Trial Profile
A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Xenikos
- 16 Nov 2018 According a Xenikos media release, data from the study were published online in the peer-reviewed journal, Biology of Blood and Marrow Transplantation
- 16 Nov 2018 Results published in the Media Release
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology